William Blair Estimates CVRx’s FY2024 Earnings (NASDAQ:CVRX)

CVRx, Inc. (NASDAQ:CVRX) – Analysts at William Blair lifted their FY2024 earnings per share estimates for shares of CVRx in a research note issued to investors on Tuesday, January 14th. William Blair analyst M. Andrew now anticipates that the company will earn ($2.62) per share for the year, up from their prior estimate of ($2.65). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.62) per share. William Blair also issued estimates for CVRx’s Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.64) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.82) EPS.

Several other research firms also recently weighed in on CVRX. Lake Street Capital boosted their price target on shares of CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Piper Sandler reissued an “overweight” rating and issued a $16.00 target price (up previously from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Cantor Fitzgerald restated an “overweight” rating and set a $14.00 target price on shares of CVRx in a report on Wednesday, October 23rd. Craig Hallum lifted their price target on CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Canaccord Genuity Group increased their price objective on CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, December 9th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, CVRx has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

CVRx Price Performance

Shares of CVRx stock opened at $17.62 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 10.23 and a current ratio of 11.32. CVRx has a 52-week low of $6.40 and a 52-week high of $29.23. The company has a fifty day moving average of $14.08 and a 200-day moving average of $11.09. The stock has a market capitalization of $427.46 million, a price-to-earnings ratio of -6.53 and a beta of 1.26.

CVRx (NASDAQ:CVRX) last issued its earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The firm had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $13.28 million. CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. During the same period in the prior year, the company earned ($0.43) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CVRX. Barclays PLC grew its position in shares of CVRx by 312.5% in the 3rd quarter. Barclays PLC now owns 19,067 shares of the company’s stock worth $169,000 after buying an additional 14,445 shares during the last quarter. Geode Capital Management LLC lifted its stake in CVRx by 2.2% in the third quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock worth $2,600,000 after acquiring an additional 6,443 shares during the period. XTX Topco Ltd bought a new stake in CVRx in the third quarter valued at $150,000. Jane Street Group LLC increased its position in CVRx by 36.1% during the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock valued at $168,000 after purchasing an additional 5,053 shares during the period. Finally, State Street Corp increased its position in CVRx by 11.4% during the 3rd quarter. State Street Corp now owns 264,733 shares of the company’s stock valued at $2,332,000 after purchasing an additional 27,071 shares during the period. Hedge funds and other institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.